Friday, September 4, 2026

North Korea Launches 600mm Rockets Capable of Hitting Seoul and U.S. Bases

Kim Jong Un's missile drill showcases North Korea's strike capabilities, targeting South Korea and U.S. bases, amid rising tensions.

How Celltrion Plans to Cut Biologics Development Costs by 25% Amid FDA Regulation Changes

Celltrion is optimistic about enhanced competitiveness due to eased biosimilar regulations by the FDA, expecting significant cost reductions.

Gwyneth Paltrow Brings Korean Nature to Life in New York’s Genesis House

Gwyneth Paltrow's immersive exhibition celebrates Korean forests, blending wellness and cultural storytelling in Manhattan.

Tag: ADC

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

CS5001 Breakthrough: 100% Complete Remission in DLBCL Trials – What This Means for Cancer Treatment

ABL Bio's ADC candidate shows complete response in all patients in early trials for first-line treatment of DLBCL.

Samsung Bioepis, Built on Biosimilars, Expands Growth Strategy Into Novel Drugs

Samsung Bioepis is pursuing a two-track growth strategy that combines global biosimilar expansion with next-generation novel drug development, including ADC therapies.

HyDIFFUZE™: The Game-Changer in Subcutaneous ADC Delivery for Cancer Treatment

Huons Lab patents a platform technology for ADC subcutaneous injections, enhancing stability and drug delivery efficiency in biopharmaceuticals.

LegoChem expands options beyond early ADC licensing into late-stage clinical development

LegoChem Biosciences secures funding to advance ADC therapies into late-stage trials, enhancing strategic flexibility in biotech.

ABL Bio to Showcase Dual-Target ADC Candidate ABL209 at World ADC Korea 2026

ABL Bio will showcase its dual-target ADC candidate ABL209 at the World ADC Korea 2026, focusing on enhanced cancer treatment.

How Dong-A ST’s SC5024 and ADC Innovations Could Change the Game Cancer Pipeline

Dong-A ST showcased its innovative cancer pipeline at AACR 2026, featuring promising preclinical findings and advanced therapeutic strategies.

Unlocking Cancer Treatment: Celltrion’s 4 Promising ADC Drugs Enter Patient Trials in 2026

Celltrion's ADC cancer drug candidates CT-P70, CT-P71, and CT-P73 enter patient dosing, targeting various cancers with Fast Track Designation.

CT-P71: The New ADC Cancer Drug Fast-Tracked by FDA for Urothelial Carcinoma

Celltrion's CT-P71 receives FDA Fast Track designation for urothelial carcinoma, enhancing its ADC pipeline and global drug development efforts.

ABL Bio to Invest Additional $25 Million in Neok Bio to Accelerate ADC Clinical Trials

ABL Bio invests $25M in Neok Bio for bispecific antibody-drug conjugate trials, aiming for FDA-approved treatments by 2027.

ABL209 Receives FDA Approval: What This Dual Antibody ADC Means for Cancer Treatment

ABL Bio receives FDA approval for ABL209, a bispecific antibody-drug conjugate, advancing ADC development for solid tumors.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.